PROJECT STRANDSHIFT | SCF ADVANCED MEDICINE CLINIC RESEARCH PROJECT OUTLINE

Project Title: HTT–Genome Injury–Viragenesis Neuroimmune Disease Mapping Program

Project Code: SCF-AMC-HTT-VIRAGENESIS-0001

Protocol Basis: SCF Advanced Disease Modeling & Discovery, SCF Pathophysiology, SCF Clinical Research Workflow, SCF Synergistic Compatibility Principles

Scientific Boundary Statement

Viruses are not simply broken human DNA or RNA strands. Viruses are infectious biological entities with genomes, capsid or envelope structures, replication machinery dependencies, and host-cell entry/exit programs. Human DNA injury can produce genomic instability, inflammation, apoptosis, micronuclei, retroelement activation, or “viral mimicry,” but current biology does not support spontaneous conversion of injured HTT or autoimmune/neurodevelopmental genes into new infectious viruses. DNA repair defects are linked to neurodegeneration, and endogenous retroviral elements may be reactivated in autoimmune, oncologic, and neurodegenerative contexts, but these must be distinguished from exogenous viral infection.

Core Research Questions

Question	SCF Research Translation
Are viruses broken strands of RNA or DNA?	Test viral-genome fragments, endogenous retroelements, and exogenous viral genomes separately.
Can autoimmune or neurodevelopmental genes with DNA injury become viruses?	Investigate whether damaged DNA activates retroelements, innate immune sensing, or viral-like transcripts, not de novo virus creation.
When does injured DNA become virus-like biology?	Define thresholds for micronuclei, cGAS-STING activation, interferon signaling, HERV expression, apoptosis, and viral mimicry.
Can diseased tissue DNA be mapped to specific viruses?	Compare tissue sequencing against curated viral, HERV, and human reference genomes.

Project Mission

To construct a multi-omic SCF disease-origin model for HTT gene injury, CAG instability, DNA repair deficiency, neurodegeneration, autoimmune gene activation, viral pathogen exposure, endogenous retroviral activation, apoptosis, angiogenesis, and oncologic drift, with a clinic-ready translational framework.

HTT is located at chromosome 4p16.3, and Huntington disease is caused by pathogenic CAG-repeat expansion in HTT; current references describe 36 or more CAG repeats as pathogenic or disease-associated depending on penetrance category.

Activated SCF Modules

Module	Activation Purpose
SCF Pathophysiology Protocol	Reverse-omics disease reconstruction
SCF Viragenesis Framework	Viral, retroviral, viral-mimicry, and pathogen-persistence mapping
SCF Universal Cross-System Analysis	Neuroimmune–oncologic–autoimmune convergence
SCF Fault Architecture	Molecular-to-system failure hierarchy
SCF Clinical Research Workflow	Clinic-facing operational structure
SCF PCR Braid	Preventative, curative, restorative therapeutic logic

Phase Structure

Phase	Objective	Core Assays	Mandatory Outputs
Phase 0: Disease Intelligence	Define HTT-neuroimmune-viral research scope	Literature, cohort registry, tissue map	Disease Intelligence Report
Phase 1: Disease-Origin Discovery	Identify inherited, acquired, viral, inflammatory, and DNA-injury origins	WGS, long-read sequencing, family-genetic mapping	Etiopathogenic Core
Phase 2: DNA/RNA Injury Mapping	Detect DNA breaks, repair defects, RNA instability	γH2AX, comet assay, ATAC-seq, RNA-seq, single-cell multiome	DNA Injury Atlas
Phase 3: HTT and Gene-Loci Profiling	Map HTT, DNA repair, autoimmune, neurodevelopmental, apoptosis loci	HTT CAG sizing, SNV/CNV mapping, methylation sequencing	Gene-Loci Fault Matrix
Phase 4: Viral/Retroviral Discrimination	Separate exogenous viruses from HERVs and viral mimicry	Metagenomic sequencing, virome capture, HERV transcriptomics	Viral-Origin Classifier
Phase 5: Apoptosis and Immune-Sensing Model	Determine when DNA injury triggers innate immunity or cell death	cGAS-STING, IFN-I, caspase-3/7, TUNEL	Apoptosis–Viragenesis Map
Phase 6: Oncologic Angiogenesis Convergence	Assess hypoxia, angiogenesis, tumor-like tissue remodeling	VEGF, HIF-1α, endothelial markers, spatial transcriptomics	Angiogenesis Risk Matrix
Phase 7: Tissue-to-Virus Mapping	Compare diseased tissue signals to viral references	BLAST/kraken-style viral alignment, integration-site analysis	Tissue–Virus Evidence Table
Phase 8: SCF Therapeutic Opportunity	Identify intervention targets	Target ranking, druggability, safety modeling	PCR Therapeutic Blueprint

SCF Fault Architecture Matrix

Tier	Fault Class	Candidate Markers	Interpretation
Molecular	HTT CAG expansion, DNA breaks, repair deficiency	HTT, ATM, ATR, BRCA1/2, PARP1, XRCC genes	Genome instability burden
Transcriptomic	Aberrant RNA, viral-like transcripts	RNA-seq, repeat RNA, HERV-K/W	Viral mimicry vs infection
Immune	Autoimmune activation	HLA, IFN-I, NF-κB, cGAS-STING	Sterile inflammation or pathogen-linked response
Cellular	Apoptosis, senescence	Caspases, p53, BAX/BCL2	Injury-response fate
Tissue	Neurodegeneration, inflammatory remodeling	NeuN, GFAP, IBA1, NfL	Tissue-level damage progression
Oncologic	Angiogenic drift	VEGF, HIF-1α, MMPs	Repair-to-remodeling transition

Critical Classification Logic

Finding	Classification
Human DNA break without viral sequence	DNA injury, not virus
HERV transcript activation	Endogenous retroelement activation
Viral reads matching known pathogen genome	Exogenous viral infection or contamination requiring validation
Viral-like interferon response without virus	Sterile viral mimicry
Integrated viral sequence with flanking human DNA	Possible viral integration event
Apoptotic DNA fragments	Cell-death debris, not virus

Primary Hypotheses

HTT instability and DNA repair deficiency may amplify neuroimmune inflammation and apoptosis.
DNA injury does not create viruses de novo, but may activate endogenous retroelements or viral-mimicry pathways.
Diseased tissues may contain viral signatures from infection, latent reactivation, contamination, or endogenous retroviral transcription.
Neurodegenerative and autoimmune gene networks may converge through DNA damage response, interferon signaling, apoptosis, and mitochondrial stress.

Translational Endpoints

Endpoint Type	Measures
Genomic	HTT CAG length, somatic expansion, DNA repair variants
Transcriptomic	RNA injury, HERV expression, interferon signatures
Proteomic	Mutant huntingtin, DNA repair proteins, apoptotic markers
Viral	Confirmed viral genome, integration site, replication markers
Neurodegenerative	NfL, GFAP, neuronal loss signatures
Autoimmune	HLA risk, autoantibodies, cytokine signatures
Oncologic	VEGF/HIF-1α angiogenesis axis

Regulatory Position

This is a non-interventional translational research protocol suitable for IRB review, biobank governance, genomic-data consent, CLIA/CAP-aligned confirmatory testing, and future IND-enabling therapeutic target discovery.

MASTER REGISTRY INDEX

SCF-AMC-HTT-VIRAGENESIS-0001 — HTT–Genome Injury–Viragenesis Research Program

SCF-DMRD-MASTER-0001 — SCF Advanced Disease Modeling & Discovery Master Template

SCF-PATH-UT-0001 — SCF Pathophysiology Protocol

SCF-VIRAGENESIS-0001 — SCF Viragenesis Framework

SCF-UCSA-0001 — Universal Cross-System Analysis Framework

SCF-CRD-WORKFLOW-0001 — SCF Clinical Research & Development Workflow

SCF-PCR-0001 — Preventative–Curative–Restorative Therapeutic Braid